Alnylam Pharmaceuticals
ALNY
$287.80
+1.75%
Alnylam Pharmaceuticals is a biotechnology company and a pioneer in RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. The company is a clear market leader in RNAi, having successfully developed and commercialized multiple drugs for rare diseases like hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. The current investor narrative revolves around the company's transition from a research-focused entity to a profitable commercial-stage biotech, with recent quarterly results showing significant revenue growth and a path to sustainable profitability, though this is balanced against typical biotech volatility and the need for continued pipeline execution.…
ALNY
Alnylam Pharmaceuticals
$287.80
Investment Opinion: Should I buy ALNY Today?
Rating & Thesis: Hold. ALNY presents a high-conviction fundamental story of commercial success trapped in a severe technical downtrend, creating a misalignment that advises patience. While analyst sentiment is mixed but leans positive, the stock's proximity to its 52-week low suggests waiting for a confirmed reversal in price momentum before establishing a new position.
Supporting Evidence: The recommendation is supported by four key data points: 1) The dramatic profitability turnaround, with Q4 net income of $186.4M vs. a prior-year loss, 2) Robust forward growth implied by a forward P/E of 20.55x, which is modest for a commercial biotech leader, 3) Strong underlying financial health indicated by a 39.76% ROE and $465.4M in TTM free cash flow, and 4) The stock's extreme technical oversold condition, trading just 0.5% above its 52-week low, which may limit near-term downside.
Risks & Conditions: The two biggest risks are a breakdown below the $282 support level, which could accelerate the downtrend, and any deceleration in the explosive revenue growth trajectory below analyst expectations. This Hold rating would upgrade to a Buy on a confirmed technical reversal above key resistance (e.g., a sustained move above $330) coupled with continued quarterly execution that meets or beats estimates. It would downgrade to a Sell on a decisive break below the 52-week low with high volume, signaling a complete failure of the fundamental story to support the price. Relative to its history and the growth implied by its forward multiple, the stock appears fairly valued to slightly undervalued, but the technical overhang is severe.
Sign up to view all
ALNY 12-Month Price Forecast
The outlook for ALNY is bifurcated. The fundamental case for a profitable, growing RNAi leader is strong and supported by hard data. However, the technical and sentiment picture is dire, with the stock acting as a 'falling knife' that has ignored improving fundamentals. The base case of consolidation and gradual recovery is most probable, but the path is fraught with volatility. The stance is neutral due to this conflict; the data supports ownership, but the price action screams caution. Confidence is medium because the resolution hinges on the next few quarterly reports. The stance would upgrade to bullish on a confirmed technical reversal above key resistance ($330) with sustained fundamental execution. It would turn bearish on a breakdown below $282 coupled with a material deterioration in commercial metrics.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $374.14 and implied upside of +30.0% versus the current price.
Average Target
$374.14
10 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
10
covering this stock
Price Range
$230 - $374
Analyst target range
The stock is covered by 10 analysts, indicating solid institutional interest. While specific consensus ratings and price targets are not provided in the dataset, recent institutional rating actions show a pattern of reiterated bullishness, with firms like HC Wainwright, Chardan Capital, and Needham maintaining 'Buy' ratings as recently as February and March 2026. However, a notable downgrade from Jefferies from 'Buy' to 'Hold' on March 16, 2026, introduces a note of caution amidst the generally positive sentiment. The absence of explicit target prices in the data limits the calculation of implied upside, but the analyst revenue estimates for the coming year average $11.74 billion, with a wide range from $10.97 billion to $13.73 billion. This broad spread signals high uncertainty and debate among analysts regarding the company's near-term commercial trajectory. The pattern of recent ratings suggests the investment community is closely watching execution on the path to profitability, with upgrades and downgrades likely to drive near-term volatility.
Bulls vs Bears: ALNY Investment Factors
The investment debate for ALNY is a classic clash between compelling fundamentals and dire technicals. The bull case is anchored in a dramatic financial transformation—explosive 85% revenue growth, a swing to profitability, and strong free cash flow—all supported by a reasonable forward P/E of 20.6x. The bear case is dominated by severe price action, with the stock down 29% in six months and languishing at its 52-week low, reflecting deep investor skepticism. Currently, the bearish technical momentum appears to have the upper hand, overwhelming the positive fundamental story. The single most important tension is whether the company's proven commercial execution and path to sustainable profits can finally arrest the technical downtrend and rebuild investor confidence, or if further negative sentiment and potential execution missteps will keep the stock in a 'falling knife' scenario.
Bullish
- Dramatic Profitability Turnaround: The company swung from a net loss of $83.76 million in Q4 2024 to a net income of $186.42 million in Q4 2025, demonstrating a successful transition to a profitable commercial-stage biotech. This is further evidenced by a trailing twelve-month free cash flow of $465.38 million, confirming sustainable cash generation.
- Explosive Revenue Growth Trajectory: Q4 2025 revenue grew 84.95% year-over-year to $1.097 billion, highlighting strong commercial execution for its RNAi therapeutics. Analyst consensus projects average revenue of $11.74 billion for the coming year, implying continued significant growth expectations.
- Attractive Forward Valuation: The forward P/E ratio of 20.55x is reasonable for a commercial-stage biotech leader, especially when contrasted with the trailing P/E of 166.04x. This forward multiple suggests the market is pricing in the earnings surge from the company's newfound profitability.
- Strong Financial Health & Capital Efficiency: The balance sheet shows robust liquidity with a current ratio of 2.76 and a high return on equity of 39.76%, indicating efficient use of capital. While the debt-to-equity ratio of 1.62 indicates leverage, it is manageable for a growth-stage company with positive cash flow.
Bearish
- Severe Technical Downtrend & Weakness: The stock is down 28.85% over six months and is trading at $282.85, just above its 52-week low of $281.77, indicating extreme price weakness. This places it in the bottom 0.5% of its 52-week range, suggesting a lack of buyer conviction and potential for further technical selling.
- Lumpy & Volatile Quarterly Revenue: Despite strong YoY growth, Q4 2025 revenue of $1.097 billion represents a sequential drop from Q3's $1.249 billion, highlighting quarter-to-quarter variability. This lumpiness introduces uncertainty and makes near-term forecasting difficult, as reflected in the wide analyst revenue estimate range of $11.0B to $13.7B.
- High Trailing Valuation & Execution Risk: The trailing P/E of 166.04x, while down from a peak of 256.27x, remains extremely elevated and embeds perfection in future growth. Any stumble in commercial execution, pipeline development, or a slowdown in revenue growth could trigger a severe multiple compression.
- Recent Analyst Downgrade Signals Caution: Jefferies downgraded ALNY from 'Buy' to 'Hold' on March 16, 2026, introducing a note of caution against the backdrop of generally positive sentiment. This action reflects growing concerns about the stock's risk/reward profile after its significant decline.
ALNY Technical Analysis
ALNY is in a pronounced downtrend, with its price down 28.85% over the last six months and 7.16% over the past year. The stock is currently trading at $282.85, which is just above its 52-week low of $281.77, positioning it at the very bottom (approximately 0.5%) of its 52-week range; this indicates extreme weakness and suggests the stock is either a deep value opportunity or a falling knife, depending on the fundamental outlook. Recent momentum shows continued pressure, with the stock down 2.96% over the past month and 9.75% over the last three months, confirming the bearish trend is intact despite a low beta of 0.27, which implies the stock has been less volatile than the broader market during this decline. Key technical levels are clearly defined, with immediate support at the 52-week low of $281.77 and major resistance far above at the 52-week high of $495.55. A decisive breakdown below the $282 support level could trigger further technical selling, while any recovery would need to overcome significant overhead supply. The stock's beta of 0.267 indicates it has been about 73% less volatile than the S&P 500 (SPY), which has gained 22.86% over the past year, highlighting ALNY's severe underperformance and idiosyncratic risk profile that demands careful position sizing.
Beta
0.27
0.27x market volatility
Max Drawdown
-42.4%
Largest decline past year
52-Week Range
$281-$496
Price range past year
Annual Return
-6.6%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | +0.3% | +2.1% |
| 3m | -10.2% | +12.5% |
| 6m | -26.6% | +12.4% |
| 1y | -6.6% | +26.4% |
| ytd | -28.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth has been explosive but volatile, with Q4 2025 revenue of $1.097 billion representing an 84.95% year-over-year increase. However, this follows a pattern of lumpy quarterly sales, as seen in the sequential drop from Q3's $1.249 billion, indicating potential quarter-to-quarter variability in product shipments and partner revenues. The revenue segment data highlights GIVLAARI as a key driver with $160.67 million in the period, significantly outpacing ONPATTRO's $70.76 million, suggesting a successful product lifecycle management strategy. Profitability has dramatically improved, with the company reporting net income of $186.42 million and a gross margin of 75.6% in Q4 2025. This marks a stark turnaround from losses in prior quarters, such as a net loss of $83.76 million in Q4 2024, demonstrating effective scaling and cost management. The trailing twelve-month free cash flow of $465.38 million further supports the shift to sustainable cash generation, a critical milestone for the investment thesis. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure for a growth biotech. Financial health is robust, with a current ratio of 2.76 providing ample short-term liquidity. The return on equity of 39.76% is exceptionally high, reflecting the efficient use of shareholder capital to generate profits following the recent transition to profitability.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income of $186.42 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is extremely high at 166.04x, while the forward PE is a more reasonable 20.55x; this massive gap implies the market expects a dramatic normalization and surge in earnings over the next twelve months, pricing in the company's newfound profitability. Compared to typical biotechnology industry averages, which often trade at high multiples due to growth expectations, ALNY's forward PE of 20.55x appears relatively modest for a commercial-stage leader with proven technology. The stock's Price-to-Sales ratio of 14.03x and EV-to-Sales of 9.00x also suggest a premium valuation that is likely justified by its proprietary RNAi platform and path to sustained profitability, rather than speculative pipeline value alone. Historically, the stock's own valuation has been highly volatile. The current trailing PE of 166.04x is below the extreme historical highs seen in recent quarters (e.g., a PE of 256.27 in Q3 2025) but remains elevated. This positioning suggests that while the market has repriced the stock lower from peak optimism, it still embeds significant growth expectations, leaving it vulnerable to disappointment if execution falters.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: ALNY's primary financial risk stems from its elevated valuation and the high expectations embedded within it. The trailing P/E of 166x and Price-to-Sales of 14x demand flawless execution of its growth trajectory, estimated at $11.7B in revenue for the coming year. Any quarter-to-quarter revenue volatility, as seen in the sequential drop from Q3 to Q4 2025, could trigger significant multiple compression. Furthermore, while the debt-to-equity ratio of 1.62 is manageable, it represents a leveraged capital structure that increases financial risk if cash flow generation were to falter.
Market & Competitive Risks: The stock faces acute valuation compression risk, trading near 52-week lows despite improved fundamentals, indicating the market is discounting future prospects. Its low beta of 0.27 has not protected it, as it has severely underperformed the rising market by over 30% in the past year, highlighting intense idiosyncratic and sector-specific selling pressure. Competitive risks are inherent in biotechnology, where next-generation therapies or adverse clinical data from pipeline candidates could rapidly erode the commercial moat of its current RNAi franchise.
Worst-Case Scenario: The worst-case scenario involves a combination of a commercial misstep, such as a significant revenue miss or guidance cut, coinciding with a broader biotech sector downturn. This could break the critical technical support at the 52-week low of $281.77, triggering accelerated algorithmic and momentum selling. Given the stock's 42.4% maximum drawdown and the distance to its 52-week high of $495.55, a realistic adverse scenario could see a further decline of 20-30% from current levels, potentially testing prices in the low $200s, representing a loss of roughly -$60 to -$85 per share from the current $282.85.
FAQ
The key risks are: 1) Technical & Sentiment Risk: The stock is in a pronounced downtrend, down 29% in six months and at its 52-week low, indicating severe selling pressure that could continue. 2) Execution & Volatility Risk: Quarterly revenue has been lumpy (sequential drop in Q4), and any miss against high analyst expectations (avg. $11.74B) could crash the valuation. 3) Financial Risk: A debt-to-equity ratio of 1.62 introduces leverage, though it is currently supported by positive cash flow. 4) Competitive/Clinical Risk: Biotechnology is inherently risky, with pipeline setbacks or new competitive therapies posing threats to long-term growth.
The 12-month forecast is scenario-dependent. The base case (50% probability) sees the stock consolidating and recovering to a range of $300-$380 as it proves the sustainability of its profitability, aligning with a stabilization of its forward P/E multiple. The bull case (30% probability) targets $400-$495 on flawless execution and multiple expansion. The bear case (20% probability) warns of a drop to $240-$282 if commercial execution falters and technical support breaks. The base case is most likely, assuming the company meets consensus revenue estimates around $11.7 billion.
ALNY's valuation presents a mixed picture. Based on trailing earnings, it appears extremely overvalued with a P/E of 166x. However, the market is pricing forward, and the forward P/E of 20.6x is modest for a commercial-stage biotech leader with its growth profile, suggesting it may be fairly valued or even slightly undervalued if execution continues. The key is the Price-to-Sales ratio of 14x, which implies a premium for its proprietary platform. Overall, the valuation is fair relative to its growth prospects but carries high execution risk.
ALNY is a compelling but high-risk investment at current levels. The fundamental case is strong, with 85% YoY revenue growth, a swing to profitability, and a reasonable forward P/E of 20.6x. However, it is a 'good buy' only for investors with a high risk tolerance and a long-term horizon, given the stock is in a severe technical downtrend and trading at its 52-week low. The biggest near-term risk is a breakdown below $282 support, which could lead to further declines. For most investors, it may be prudent to wait for a confirmed reversal in price momentum before buying.
ALNY is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. Its value proposition is based on the multi-year commercial rollout of its RNAi platform and pipeline development, not short-term trading catalysts. The stock's low beta of 0.27 but high idiosyncratic volatility (-29% YTD) makes it unsuitable for short-term traders seeking stable price action. Long-term investors can potentially look through the current technical weakness to capture the growth from its transition to a profitable enterprise, but must be prepared for significant interim volatility.
